PLC To Begin US Trial For RenalGuard - Worcester Business Journal Print
Worcester Business Journal
The study builds on two previous European trials that showed reductions in incident rates of contrast-induced nephropathy, or CIN, PLC said. The condition can lead to renal failure and has a mortality rate of as high as 35 percent. ...
PLC Systems Receives FDA Approval to Commence Pivotal Study of RenalGuard in

...